Home
Storia in 5 fonti
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
- ·
cnbc.com
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
- ·
ilsole24ore.com
Novo Nordisk rilancia l’offerta su Metsera a 10 miliardi di dollari
La società danese propone il pagamento in contanti di 62,20 dollari per azione, rispetto ai 56,50 dollari della precedente offerta
